20,256 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC purchased a new position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 20,256 shares of the company’s stock, valued at approximately $34,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC grew its holdings in shares of Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after buying an additional 9,904 shares during the last quarter. Barclays PLC grew its holdings in shares of Nautilus Biotechnology by 17.9% during the fourth quarter. Barclays PLC now owns 125,204 shares of the company’s stock worth $210,000 after buying an additional 19,030 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Nautilus Biotechnology during the fourth quarter worth about $28,000. Hsbc Holdings PLC grew its holdings in shares of Nautilus Biotechnology by 182.5% during the fourth quarter. Hsbc Holdings PLC now owns 55,184 shares of the company’s stock worth $92,000 after buying an additional 35,650 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Nautilus Biotechnology by 11.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 770,353 shares of the company’s stock worth $1,294,000 after buying an additional 78,367 shares during the last quarter. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Guggenheim set a $2.50 price target on Nautilus Biotechnology in a report on Friday, February 28th.

Nautilus Biotechnology Trading Down 2.9%

Shares of NAUT opened at $0.80 on Tuesday. Nautilus Biotechnology, Inc. has a twelve month low of $0.66 and a twelve month high of $3.09. The stock’s 50 day moving average is $0.82 and its two-hundred day moving average is $1.51. The firm has a market capitalization of $100.92 million, a PE ratio of -1.43 and a beta of 1.41.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Tuesday, April 29th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. On average, sell-side analysts predict that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Insider Buying and Selling at Nautilus Biotechnology

In other news, CEO Sujal M. Patel purchased 53,300 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The shares were acquired at an average price of $0.99 per share, with a total value of $52,767.00. Following the purchase, the chief executive officer now directly owns 10,117,788 shares of the company’s stock, valued at $10,016,610.12. The trade was a 0.53% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have acquired 66,800 shares of company stock valued at $62,622. 41.10% of the stock is owned by corporate insiders.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.